Navigation Links
Pharmaceutical Institute Hires Nathan Pienkowski, Ph.D., to Head Instructional Design
Date:12/15/2010

RALEIGH, N.C., Dec. 15, 2010 /PRNewswire/ -- Pharmaceutical Institute, a leading provider of specialized training solutions for the pharmaceutical and biotech industry and a subsidiary of Campbell Alliance, has appointed Nathan Pienkowski, Ph.D., as Instructional Design Director.  In this role, Mr. Pienkowski will oversee the instructional quality of Pharmaceutical Institute's customized and commercially available courses within the industry's largest catalog of specialized training solutions.

Mr. Pienkowski has 15 years experience in course development, training, and learning technology development within the healthcare and pharmaceutical industry.  Prior to joining the Pharmaceutical Institute, Mr. Pienkowski served as a senior-level management consultant and principal of a consulting firm dedicated to education and training.  While there, he managed the development of custom training solutions for many of the industry's leading drug companies.

"Nathan's outstanding instructional design background, coupled with his track record of success as a high-level training consultant within pharma and biotech, is an exceptional fit," says Garry O'Grady, Senior Vice President and General Manager of Pharmaceutical Institute.  "To meet the next-level training needs of our clients, we seek only the best talent.  We are confident that Nathan will contribute to the enrichment and expansion of Pharmaceutical Institute's leading-edge course offerings."

Mr. Pienkowski received his doctorate and master's degree in Instructional Systems Design, as well as a bachelor's degree, from Virginia Polytechnic Institute and State University (Virginia Tech).

About the Pharmaceutical Institute

Pharmaceutical Institute is a leading provider of specialized training programs for the pharmaceutical and biotech industry.  We partner with subject matter experts from our parent company, Campbell Alliance, to develop high-impact distance learning solutions for professionals within all major pharmaceutical company functions including Brand Management, Business Development, Clinical Development, Managed Markets, Medical Affairs, Sales, and Trade and Distribution.  The Pharmaceutical Institute is based in Raleigh, N.C.  For more information, please visit www.pharmainstitute.com.


'/>"/>
SOURCE Pharmaceutical Institute
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
(Date:5/24/2016)... --   , ... Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung des ... guter , Reinigung des ... (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... der MORA-Studie der Phase III für NER1006 (1 ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... ... ... With over 60 percent of acute stroke survivors being left unable to ... in the rehabilitation process has steadily increased. Ekso Bionics had been working to help ... stroke. , Ekso Bionics has now received clearance from the U.S. Food and Drug ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research commissioned ... dogs straight off the grill. Of the 90 percent of Americans who say they ... hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving (9 ...
(Date:5/26/2016)... , ... May 26, 2016 , ... Connor Sports, ... basketball as a partner for the Tamika Catchings Legacy Tour that will ... industry leader in hardwood basketball surfaces in all forms and levels of the game, ...
Breaking Medicine News(10 mins):